Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer have?
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer has 382 citations in the OpenAlex counts ScholarIQ stores.
When was Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer published?
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer has 2023 year in the ScholarIQ index.
What is the open-access status of Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer?
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer has green oa status in the ScholarIQ index.
What is the DOI of Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer?
The DOI for Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer is on the source record.
What is the PMID of Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer?
The PMID for Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer is on the source record.
What is the OpenAlex record for Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer?
The OpenAlex for Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer is on the source record.